From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy
Author(s) -
Nivaldo Linares-Pérez,
María Eugenia Toledo-Romaní,
Darielys Santana-Mederos,
Anai García-Fariñas,
Dagmar García-Rivera,
Yury Valdés-Balbín,
Vicente Vérez-Bencomo
Publication year - 2017
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2017.03.011
Subject(s) - pneumococcal conjugate vaccine , herd immunity , herd , pneumococcal disease , medicine , conjugate vaccine , virology , conjugate , streptococcus pneumoniae , immunology , vaccination , biology , immunization , microbiology and biotechnology , antigen , mathematics , veterinary medicine , mathematical analysis , antibiotics
A new pneumococcal conjugate vaccine is currently undergoing advanced clinical evaluation prior to its planned introduction in Cuba. The implementation of the pneumococcal vaccination strategy has been designed with consideration of the need to maximize both its direct and indirect effects. A novel approach is suggested, which addresses preschool children as the first-line target group to generate herd immunity in infants and to have an impact on transmission at the community level. The clinical evaluation pipeline is described herein, including evaluations of effectiveness, cost-effectiveness, and impact. The scientific contribution of the Cuban strategy could support a paradigm shift from individual protection to a population effect based on a rigorous body of scientific evidence.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom